Study #2016-0991
A PHASE 1 MULTIDOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF XmAb13676 IN PATIENTS WITH CD20-EXPRESSING HEMATOLOGIC MALIGNANCIES
Study Status
Open
Treatment Agent
XmAb 13676
Principal Investigator
William G. Wierda
Description
The goal of this clinical research study is to learn about the safety of giving XmAb13676 to patients with certain types of blood, lymph, or bone marrow cancer. Researchers also want to find the highest tolerable dose and/or recommended dose and schedule of XmAb13676. This is the first study using XmAb13676 in humans.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: XmAb 13676
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Xencor, Inc.
Study Status
IRB Review and Approval Date: 06/13/2017
Recruitment Status: Open
Projected Accrual: 66
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase I
Physician name:
William G. Wierda
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789